- Home
- IVAC vs SGMT Comparison
IVAC vs SGMT Comparison
Compare IVAC & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVAC
- SGMT
- Stock Information
- Founded
- IVAC 1990
- SGMT 2006
- Country
- IVAC United States
- SGMT United States
- Employees
- IVAC N/A
- SGMT N/A
- Industry
- IVAC Industrial Machinery/Components
- SGMT
- Sector
- IVAC Technology
- SGMT
- Exchange
- IVAC Nasdaq
- SGMT Nasdaq
- Market Cap
- IVAC 88.8M
- SGMT 93.7M
- IPO Year
- IVAC 1995
- SGMT 2023
- Fundamental
- Price
- IVAC $2.65
- SGMT $5.18
- Analyst Decision
- IVAC Hold
- SGMT Strong Buy
- Analyst Count
- IVAC 1
- SGMT 5
- Target Price
- IVAC N/A
- SGMT $21.60
- AVG Volume (30 Days)
- IVAC 113.3K
- SGMT 772.8K
- Earning Date
- IVAC 11-11-2024
- SGMT 11-13-2024
- Dividend Yield
- IVAC N/A
- SGMT N/A
- EPS Growth
- IVAC N/A
- SGMT N/A
- EPS
- IVAC N/A
- SGMT N/A
- Revenue
- IVAC $65,569,000.00
- SGMT $2,000,000.00
- Revenue This Year
- IVAC N/A
- SGMT N/A
- Revenue Next Year
- IVAC N/A
- SGMT N/A
- P/E Ratio
- IVAC N/A
- SGMT N/A
- Revenue Growth
- IVAC 28.52
- SGMT N/A
- 52 Week Low
- IVAC $2.46
- SGMT $2.25
- 52 Week High
- IVAC $4.57
- SGMT $20.71
- Technical
- Relative Strength Index (RSI)
- IVAC 21.16
- SGMT 47.83
- Support Level
- IVAC $2.46
- SGMT $5.61
- Resistance Level
- IVAC $3.43
- SGMT $6.40
- Average True Range (ATR)
- IVAC 0.15
- SGMT 0.52
- MACD
- IVAC -0.09
- SGMT -0.10
- Stochastic Oscillator
- IVAC 4.13
- SGMT 17.57
About IVAC Intevac Inc.
Intevac Inc designs and develops high-productivity, thin-film processing systems. The company's production platforms are designed for high-volume manufacturing of substrates with precise thin-film properties, such as the hard disk drive, display cover panel. The Thin Film Equipment segment also previously designed, developed, and marketed manufacturing equipment for the photovoltaic solar cell and semiconductor packaging industries. Geographically, the majority of revenue is generated from Asia.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).